Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leela Barham

Set Alert for Articles By Leela Barham

Latest From Leela Barham

UK To Cut Company Payments Under Statutory Pricing Scheme

Companies that are part of the statutory pricing scheme could pay up to £6m less in 2020 under government proposals to cut percentage payments on their sales to the National Health Service. 

United Kingdom Pricing Debate

Is NICE’s Pricing Influence On The Wane?

The pricing of medicines may appear as a mystery to many; theories range from what the market will bear to prices being based on value. The Pink Sheet examines the role of two key players with influence in drug pricing in the UK – health technology assessment body NICE, which decides whether a product is value for money, and NHS England, which leads the tax-funded national health service in England and pays for new specialized drugs.

Europe United Kingdom

Concerns Emerge Over England’s Desire For Even Lower Drug Prices

With the emphasis on getting lower prices even for cost-effective drugs, England’s proposed commercial framework may be sending a negative signal to global companies.

Pricing Strategies United Kingdom

We Need To Talk – When To Get Early Scientific Advice

Hearing direct from HTA agencies on what evidence they want to see is now an option through early dialogue. With many options for early dialogue available, it is hard for companies to know whether to get advice, from which agency and how to get the most out of the dialogue.

BioPharmaceutical Europe

Fair Pricing A Key Feature Of NHS England Drug Funding Proposals

Plans for a new commercial framework for publicly funded medicines in England are out for consultation. The concept of fair and responsible pricing figures large in the proposals.

Pricing Debate United Kingdom

Metrics For Measuring UK Pricing Scheme Success: Good Start But More Work Needed

The Pink Sheet’s freedom of information request relating to the 2019 pricing and access to branded medicines scheme has shed light on the metrics being used to gauge whether the scheme is delivering on its promise.

United Kingdom Europe
See All
UsernamePublicRestriction

Register